Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

Table 1 Gender and Age Distribution of ICIs-Related Myocarditis

	Pembrolizumab		Nivolumab		Atezolizumab		Avelumab		Durvalumab		Cemiplimab		Ipilimumab
	EV	FAERS	EV	FAERS	EV	FAERS	EV	FAERS	EV	FAERS	EV	FAERS	EV	FAERS
Total	177	46	296	309	26	70	2	16	18	11	2	3	104	155
Age distribution
< 18Y	0	0	0	43	0	5	0	0	0	1	0	3	0	20
18-64Y	37	14	55	93	11	33	0	7	3	0	0	0	19	41
65-85Y	96	26	82	170	12	31	2	9	8	5	0	0	28	94
> 85Y	6	6	3	3	0	0	0	0	1	1	0	0	0	0
Unknown	38	0	156	0	3	1	0	0	6	4	2	0	57	0
Gender distribution
Female	50	15	94	113	12	27	0	5	5	0	0	0	34	53
Male	117	25	188	172	14	40	2	10	11	10	0	2	65	89
Unknown	10	6	14	24	0	3	0	1	2	1	2	1	5	13

Abbreviations: ICIs immune checkpoint inhibitors; EV EudraVigilance; FAERS Food and Drug Administration (FDA) Adverse Event Reporting System

ISSN: 1471-2407